TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has taken significant steps to advance its RNA-based therapeutic pipeline by appointing Dr. Anna Moore as Chair of its Scientific Advisory Board and entering into a sponsored research agreement with Michigan State University, the company announced recently.
Dr. Moore, a leading expert in molecular imaging and nanomedicine, will provide strategic guidance on the company’s research and development efforts focused on treating advanced cancers. Her appointment is expected to bolster TransCode’s scientific leadership as it progresses its lead candidate, TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis.
The sponsored research agreement with Michigan State University is aimed at supporting the development of TTX-MC138, including evaluation in combination with other therapies. This collaboration is crucial for advancing the candidate through preclinical and clinical stages, potentially offering new treatment options for patients with high-risk and advanced cancers.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA-based therapies for the treatment of high-risk and advanced cancer. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The news highlights the growing interest in RNA-based therapeutics and the importance of academic collaborations in drug development. By partnering with Michigan State University, TransCode gains access to cutting-edge research and expertise that could accelerate the development of its pipeline. Similarly, Dr. Moore’s appointment underscores the company’s commitment to scientific rigor and strategic oversight.
Investors and industry observers are closely watching TransCode’s progress, as the company addresses a significant unmet medical need in metastatic cancer. The latest developments could have implications for the broader field of RNA therapeutics, which has gained traction following the success of mRNA vaccines.
For more information on TransCode Therapeutics and its latest news, visit the company’s newsroom at https://ibn.fm/RNAZ.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University.